Multicenter Phase II-Trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux in Patients With R0 or R1 Resected Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Cetuximab (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 12 Jul 2011 EudraCT reports planned end date is 20 Jan 2012.